Life sciences firm Elasmogen secures £1.2m injection

Scottish Investment Bank chief Kerry Sharp hailed 'significant progress' at Aberdeen-based Elasmogen. Picture: Contributed
Scottish Investment Bank chief Kerry Sharp hailed 'significant progress' at Aberdeen-based Elasmogen. Picture: Contributed
Share this article
0
Have your say

An Aberdeen-based life sciences firm has won £1.2 million worth of funding to progress its work to develop treatments for eye diseases.

Elasmogen has received a grant from the UK’s innovation agency, Innovate UK, along with equity investment from Chester-based Deepbridge Capital and the Scottish Investment Bank (SIB), the investment arm of Scottish Enterprise.

• READ MORE: £8bn goal for a life sciences sector in rude health

The funding will be used to develop the company’s work aimed at tackling diseases such as uveitis and macular degeneration. The treatments avoid the need for direct injection into the eye and reduce side effects compared to existing treatments.

200 Voices: find out more about the people who have shaped Scotland

Aberdeen University spinout Elasmogen has taken part in Scottish Enterprise’s high-growth spinout programme which helps researchers to take their ideas and inventions from the lab to the global marketplace

Kerry Sharp, head of the SIB, said: “The company has made significant technical progress in a short space of time and its sight-saving auto-immune therapies have the potential to make a notable social, as well as commercial, impact.

“We look forward to working with Deepbridge Capital to further support and nurture the exciting opportunity presented by Elasmogen.”

The company has recently completed proof of concept trials and the funding will help it prepare its treatments for clinical trials.

Click here to ‘Like’ The Scotsman Business on Facebook